Valeant has drawn scrutiny from Congress, hospitals and patients for sharply increasing their prices, the NYT reports.» Read More
To avoid mass departures, Valeant Pharmaceuticals International will likely offer cash and stock incentives to more key staff.
Biren Amin, senior biotechnology analyst at Jefferies, discusses the developments and costs in the biotech and pharmaceuticals sector.
Arie Belldegrun, CEO of Kite Pharma, outlines the technology his company is developing for cancer treatment.
After two weeks of availability, a total of 80 prescriptions were filled for Addyi through October 30, reports STAT.
A U.S. House of Representatives investigative panel said it plans to hold a 2016 hearing on skyrocketing drug costs.
Shares of over-the-counter drugmaker Perrigo sank early Friday after its stock owners rejected a hostile, $26 billion takeover bid from Mylan.
Dr. Andre Choulika, Cellectis CEO discusses progress made in developing immunotherapy drugs through genetically modified cells.
David Amsellem, Sr. Research Analyst, Piper Jaffray, discusses Citron's report questioning Mallinckrodt's business model.
CNBC's Meg Tirrell offers an update on the war of words between Mallinckrodt and Citron Research.
Chart analyst Mark Newton believes there may be some cracks in this recent stock market rally. Here's why...
The head of short-selling firm Citron Research on Tuesday called for more disclosures about Mallinckrodt's main drug.
Shares of Valeant are falling after the call, as questions remain on Philidor, with CNBC's Meg Tirrell.
As of last week, Philidor Rx Services has stopped adjudicating insurance claims for drugs, Valeant CEO Mike Pearson said.
CNBC's Meg Tirrell highlights the short-seller's next target in the biotech space.
Corey Davis, Canaccord Genuity, discusses whether now's the time to buy Valeant, given the stock's recent 50 percent drop.
Shares of Mallinckrodt dropped today after Citron Research said it was a far worse offender of the reimbursement system than Valeant. CNBC's Meg Tirrell reports.
Valeant's stock has plunged significantly on the heels of concerns about the drugmaker's dealings with an outside pharmacy.
Some of those generic pills you buy at the drug store could change ownership Friday.
Hedge fund manager Bill Ackman reiterated his confidence in Valeant Pharmaceuticals to clients after shares tumbled more than 50 percent.
Despite allegations against it, Valeant may still have some bright spots that could be attractive for investors, says a senior analyst.
Get the best of CNBC in your inbox